Evidence map›Paper›PMID 27401214›Full record

ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2016

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Saiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, Fred R Hirsch, Gregory J Riely, Vassiliki Papadimitrakopoulou, Dickran Kazandjian, Sean Khozin, Erin Larkins, Dane J Dickson and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Saiama N WaqarDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Philip D BonomiRush University Medical Center, Chicago, Illinois.
Ramaswamy GovindanDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Fred R HirschUniversity of Colorado Cancer Center, Denver, Colorado.
Gregory J RielyMemorial Sloan Kettering Cancer Center, New York, New York.
Vassiliki PapadimitrakopoulouThe University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Dickran KazandjianU.S. Food and Drug Administration, Silver Spring, Maryland.
Sean KhozinU.S. Food and Drug Administration, Silver Spring, Maryland.
Erin LarkinsU.S. Food and Drug Administration, Silver Spring, Maryland.
Dane J DicksonOregon Health and Science University, Portland, Oregon.
Shakun MalikNational Cancer Institute, Bethesda, Maryland.
Leora HornVanderbilt University Medical Center, Nashville, Tennessee.
Andrea FerrisLUNGevity Foundation, Bethesda, Maryland.
Alice T ShawMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Pasi A JänneDana Farber Cancer Institute, Boston, Massachusetts.
Tony S K MokThe Chinese University of Hong Kong, Hong Kong, People's Republic of China.
Roy HerbstYale School of Medicine, New Haven, Connecticut.
Patricia KeeganU.S. Food and Drug Administration, Silver Spring, Maryland.
Richard PazdurU.S. Food and Drug Administration, Silver Spring, Maryland.
Gideon M BlumenthalU.S. Food and Drug Administration, Silver Spring, Maryland. Electronic address: Gideon.Blumenthal@fda.hhs.gov.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
Washington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7M
NCATS NIH HHS UL1 TR001863NCI NIH HHS K12 CA090625NCI NIH HHS K12 CA167540NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.

Indexed as

Drug DiscoveryB7-H1 AntigenClinical Trials as TopicDisease-Free SurvivalErbB ReceptorsHumansImmunotherapyLung NeoplasmsMolecular Targeted TherapyMutationResearch DesignB7-H1 AntigenErbB ReceptorsClinical trialsImmunotherapyLung cancerTargeted therapy

Identifiers

PMID27401214
PMCPMC5131641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.